Analysis of hospital registry data found that people who were hospitalized due to bleeding in the brain and who had taken multiple antiplatelet medications, or medications stronger than aspirin, were ...

Analysis of hospital registry data found that people who were hospitalized due to bleeding in the brain and who had taken multiple antiplatelet medications, or medications stronger than aspirin, were ...

Abbreviated dual antiplatelet therapy after percutaneous coronary intervention using third-generation stents remained ...

DUBLIN--(BUSINESS WIRE)--The "Antiplatelet Market: Analysis By Drug Class, By Route of Administration, By Distribution Channel, By Region Size and Trends" report has been added to ...

Findings from the Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry demonstrate that single antiplatelet therapy (SAPT) after transcatheter aortic valve ...

London, United Kingdom – 1 September 2024: Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic ...

Washington, D.C. – MAY 1, 2025 – Findings from the Transfusion Requirements in Transcatheter Aortic Valve Implantation (TRITAVI) registry demonstrate that single antiplatelet therapy (SAPT) after ...

The application of antiplatelet therapy in dental surgery has become a focal point for clinicians due to the dual needs of maintaining thrombotic protection while minimising perioperative bleeding ...

Current guidelines recommend dual antiplatelet therapy, a combination of aspirin and a P2Y 12 inhibitor, for 6–12 months after percutaneous coronary intervention with drug-eluting stent implantation ...